A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.

Brief description of study

You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (the activity of a drug in the body), and antitumor activity of KIN-2787 in participants with Rapidly accelerated fibrosarcoma, homolog B (BRAF) and/or Neuroblastoma- Rat sarcoma viral oncogene homolog (NRAS) mutation-positive solid tumors. Dose escalation will continue until the highest planned dose level is determined to be safe and tolerable. Dose expansion will assess preliminary evidence of the anti-cancer activity of KIN-2787 in participants with advanced or metastatic solid cancers. The study will be conducted in 2 parts. Part A comprises 2 components: 1) Dose Escalation: KIN-2787 Monotherapy (Part A1); and 2) Dose Escalation: KIN-2787 + Binimetinib Combination.(Part A2). Part B Dose Expansion will assess preliminary evidence of the anti-cancer activity of KIN-2787 in participants with advanced or metastatic solid cancers.


Clinical Study Identifier: s22-00213
ClinicalTrials.gov Identifier: NCT04913285
Principal Investigator: Janice Mehnert.
Other Investigators: Nila Theresa De La Rosa, Maya Dimitrova, Jeffrey S. Weber, Carol M Lee, Kristen Spencer, Jonathan B Kahn, Kathleen M Madden, Rafael Winograd.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.